The personalised cancer therapy company has completed a $40m round that increased its funding to $76m altogether.
Mitra Biotech, a US-based medical response analysis technology developer, has closed a $40m funding round led by venture capital firm Northpond Ventures.
<!–
p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 11.0px Helvetica}
span.s1 {font-kerning: none}
–>
VC firms Accel and Sequoia Capital, growth capital firm Sands Capital Ventures and investment manager RA Capital Management also joined the round.
Founded in 2010, Mitra is working on a platform, Canscript, that predicts how a patient will…
